93 related articles for article (PubMed ID: 8780933)
41. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
[TBL] [Abstract][Full Text] [Related]
42. mdm-2 expression in human testicular germ-cell tumors and its clinical value.
Eid H; Institoris E; Géczi L; Bodrogi I; Bak M
Anticancer Res; 1999; 19(4C):3485-90. PubMed ID: 10629640
[TBL] [Abstract][Full Text] [Related]
43. Expression of p53 and mdm-2 proteins in Hodgkin's Disease. Absence of correlation with the presence of Epstein-Barr virus.
Tzardi M; Kouvidou C; Panayiotides I; Koutsoubi K; Stefanaki K; Giannikaki E; Darivianaki K; Zois M; Eliopoulos G; Kakolyris S; Delides G; Rontogianni D; Kanavaros P
Anticancer Res; 1996; 16(5A):2813-9. PubMed ID: 8917390
[TBL] [Abstract][Full Text] [Related]
44. Immunoreactivity of new antibodies anti-p53 and anti-MDM-2 in paraffin embedded tissue samples.
Andrejco M; Kaláb M; Oulton A; Kolár Z; Lichnovský V; Kod'ousek R; Vojtĕsek B
Acta Univ Palacki Olomuc Fac Med; 1996; 140():63-7. PubMed ID: 9431695
[TBL] [Abstract][Full Text] [Related]
45. Cyclin D1, p53, mdm2, and Ki67 protein expression in preneoplastic lesions of the larynx.
Capaccio P; Carboni N; Pignataro L; Scotti A; Ottaviani F; Pruneri G
J Chemother; 1997 Apr; 9(2):113-4. PubMed ID: 9176749
[No Abstract] [Full Text] [Related]
46. mdm-2 oncogene expression in non-Hodgkin's lymphomas.
Kawamata N; Miller C; Levy V; Shintaku IP; Koeffler HP; Said JW
Diagn Mol Pathol; 1996 Mar; 5(1):33-8. PubMed ID: 8919543
[TBL] [Abstract][Full Text] [Related]
47. The mdm-2 gene is induced in response to UV light in a p53-dependent manner.
Perry ME; Piette J; Zawadzki JA; Harvey D; Levine AJ
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11623-7. PubMed ID: 8265599
[TBL] [Abstract][Full Text] [Related]
48. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics.
Momand J; Zambetti GP
Oncogene; 1996 Jun; 12(11):2279-89. PubMed ID: 8649767
[TBL] [Abstract][Full Text] [Related]
49. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
Osman I; Drobnjak M; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 Aug; 5(8):2082-8. PubMed ID: 10473090
[TBL] [Abstract][Full Text] [Related]
50. DNA binding activities of p53 protein following cisplatin damage of ovarian cells.
Wetzel CC; Berberich SJ
Oncol Res; 1998; 10(3):151-61. PubMed ID: 9700726
[TBL] [Abstract][Full Text] [Related]
51. Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance.
Ofner D; Maier H; Riedmann B; Holzberger P; Nogler M; Tötsch M; Bankfalvi A; Winde G; Böcker W; Schmid KW
Clin Mol Pathol; 1995 Feb; 48(1):M12-6. PubMed ID: 16695968
[TBL] [Abstract][Full Text] [Related]
52. The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.
Grand RJ; Lecane PS; Owen D; Grant ML; Roberts S; Levine AJ; Gallimore PH
Virology; 1995 Jul; 210(2):323-34. PubMed ID: 7618270
[TBL] [Abstract][Full Text] [Related]
53. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
54. Selective compartmentalization of different mdm2 proteins within the nucleus.
Maxwell SA
Anticancer Res; 1994; 14(6B):2541-7. PubMed ID: 7872679
[TBL] [Abstract][Full Text] [Related]
55. The predictive value of p53, MDM-2, cyclin D1 and Ki67 in the progression from low-grade dysplasia towards carcinoma of the larynx.
Pignataro L; Capaccio P; Pruneri G; Carboni N; Buffa R; Neri A; Ottaviani A
J Laryngol Otol; 1998 May; 112(5):455-9. PubMed ID: 9747474
[TBL] [Abstract][Full Text] [Related]
56. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity.
Lai R; Medeiros LJ; Wilson CS; Sun NC; Koo C; McCourty A; Brynes RK
Mod Pathol; 1998 Jul; 11(7):642-7. PubMed ID: 9688185
[TBL] [Abstract][Full Text] [Related]
57. The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop.
Almog N; Milyavsky M; Stambolsky P; Falcovitz A; Goldfinger N; Rotter V
Carcinogenesis; 2001 May; 22(5):779-85. PubMed ID: 11323398
[TBL] [Abstract][Full Text] [Related]
58. Abnormal expression of MDM-2 in breast carcinomas.
Bueso-Ramos CE; Manshouri T; Haidar MA; Yang Y; McCown P; Ordonez N; Glassman A; Sneige N; Albitar M
Breast Cancer Res Treat; 1996; 37(2):179-88. PubMed ID: 8750585
[TBL] [Abstract][Full Text] [Related]
59. Image cytometric analysis of p53 and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma of parotid gland: immunohistochemical study.
Abd-Elhamid ES; Elmalahy MH
Diagn Pathol; 2010 Nov; 5():72. PubMed ID: 21092204
[TBL] [Abstract][Full Text] [Related]
60. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53.
Ramos YF; Stad R; Attema J; Peltenburg LT; van der Eb AJ; Jochemsen AG
Cancer Res; 2001 Mar; 61(5):1839-42. PubMed ID: 11280734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
